Peter Fey

USPTO Granted Patents = 84 (Patent Applications = 7)

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 6 (Patent Applications = 14)

Average Co-Inventor Count = 5.1

ph-index = 14

Forward Citations = 827(Granted Patents)

Inventors with similar research interests:

Company Filing History:

70 out of 12,157

Bayer Aktiengesellschaft

Bayer Pharma Aktiengesellschaft

patents

4. 2 out of 721

Bayer Intellectual Property Gmbh

patents

5. 1 out of 38

Bayeraktiengesellschaft

Bayer Animal Health Gmbh

patents

8. 1 out of 76

Bayer Healthcare Aktiengesellschaft

patents

where one patent can have more than one assignee

Years Active: 1990-2025

Loading Chart...

84 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12202805 - Process for preparing (5S)-{[2-(4-carboxyphenyl)ethyl] |2-(2-{|3-chloro-4'-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]aminol-5,6,7,8-tetrahydroquinoline-2-carboxylic acid and its crystalline forms for use as pharmaceutically active compound (2025-01-21),

2. 12172996 - Methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate active compound product having improved properties, production and formulation thereof (2024-12-24),

3. 12138256 - Treatment of cardiopulmonary disorders (2024-11-12),

4. 11760737 - Process for manufacturing 4-(2,2,3,3-tetrafluoropropyl)morpholine (2023-09-19),

5. 11332444 - Method for the hydrolysis of quinolonecarboxylic esters (2022-05-17),

6. 11332435 - Method for producing (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4- chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclo-propylpropanoic acid and the crystalline form thereof for use as a pharmaceutical ingredient (2022-05-17),

7. 10633357 - Intermediates and process for preparing intermediates in the production of substituted pyrazolopyridines (2020-04-28),

8. 10633356 - Hydrates of substituted 5-fluoro-1H-pyrazolopyridines (2020-04-28),

9. 10364229 - Crystalline substituted 5-fluoro-1H-pyrazolopyridines and process for preparing (2019-07-30),

10. 9845300 - Process for preparing substituted 5-fluoro-1H-pyrazolopyridines (2017-12-19),

11. 9604948 - Process for preparing substituted 5-fluoro-1H-pyrazolopyridines (2017-03-28),

12. 9328066 - Chiral synthesis of N-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-methoxyphenyl}-1-[2,3-dihydroxy-propyl]cyclopropanesulfonamides (2016-05-03),

13. 9150573 - Process for preparing substituted 5-fluoro-1H-pyrazolopyridines (2015-10-06),

14. 8802847 - Process for preparing substituted 5-fluoro-1H-pyrazolopyridines (2014-08-12),

15. 6987185 - Method for separating methyl 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-methyl-1,4-dihydro-5-pyrimidine-carboxylate-recemate (2006-01-17),

Title: Peter Fey: Pioneering Innovation in Pharmaceuticals

Introduction:

In the realm of inventors dedicated to advancing technology for the betterment of society, Peter Fey stands as a beacon of innovation. Hailing from Wuppertal, Germany, Fey's unwavering commitment to creating a more sustainable and healthier world through his inventions has earned him recognition as a remarkable inventor in the modern era.

Latest Patents:

Peter Fey's creativity and expertise shine through his latest patents:

- "Process for manufacturing 4-(2,2,3,3-tetrafluoropropyl)morpholine": An innovative and cost-saving process for producing this vital intermediate used in the production of medicaments for cardiovascular disorders.

- "Method for producing (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4- chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclo-propylpropanoic acid": A novel process for creating this pharmaceutical ingredient crucial for treating cardiovascular, cardiopulmonary, and cardiorenal disorders.

Career Highlights:

Throughout his illustrious career, Peter Fey has collaborated with renowned companies such as Bayer Aktiengesellschaft and Adverio Pharma GmbH. His 81 patents attest to his exceptional contributions to the field of pharmaceuticals. Fey's groundbreaking work has not only revolutionized the industry but has also paved the way for transformative advancements in healthcare.

Collaborations:

In his journey towards innovation, Peter Fey has worked alongside esteemed colleagues like Walter Hubsch and Hilmar Bischoff. Together, they have pushed the boundaries of pharmaceutical research, driving towards the development of cutting-edge solutions for critical medical conditions.

Conclusion:

In conclusion, Peter Fey's tireless dedication to innovation and his passion for leveraging technology to enhance healthcare make him a true luminary in the world of inventors. His groundbreaking patents and collaborations underscore his unwavering commitment to creating a healthier and more sustainable future for generations to come. Peter Fey's legacy serves as an inspiration for aspiring inventors seeking to make a lasting impact on society.

This text is generated by artificial intelligence and may not be accurate.